or Try an Advanced Search...

    Hemophilia A Stocks List

    Symbol Grade Name % Change
    CNTA B Centessa Pharmaceuticals plc -6.32
    SGMO C Sangamo BioSciences, Inc. -4.08
    ALNY D Alnylam Pharmaceuticals, Inc. -0.77
    BAX D Baxter International Inc. 0.67
    View As Page of Charts
    Related Industries: Biotechnology Medical Instruments & Supplies
    Related Stock Lists: Hemophilia Alpha 1 Antitrypsin Antitrypsin Deficiency Biotechnology Deficiency Hemoglobin Hemoglobinopathies Huntington's Disease Life Sciences Treatment Of Hemophilia Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Autosomal Dominant Polycystic Kidney Disease Beta Thalassemia Biopharmaceutical Biosurgery Products Blastoma

    Related ETFs - A few ETFs which own one or more of the above listed Hemophilia A stocks.

    Symbol Grade Name Weight
    TPMN A The Timothy Plan Timothy Plan Market Neutral ETF 5.66
    HRTS F Tema Cardiovascular and Metabolic ETF 4.95
    PBE C PowerShares Dynamic Biotech & Genome 4.78
    GNOM F Global X Genomics & Biotechnology ETF 4.45
    MEDX F Horizon Kinetics Medical ETF 4.45
    View all Hemophilia A ETFs...
    Compare ETFs
    Compare PBE to GNOM Compare PBE to MEDX Compare TPMN to GNOM

        Hemophilia A Stocks Recent News

        Date Stock Title
        Nov 21 BAX New Strong Sell Stocks for November 21st
        Nov 19 SGMO Sangamo stock climbs 12% post-market on FDA update for ST-503
        Nov 19 BAX Baxter to Present at 7th Annual Evercore HealthCONx Conference
        Nov 19 SGMO Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Related Industries: Biotechnology Medical Instruments & Supplies
        Related Stock Lists: Hemophilia Alpha 1 Antitrypsin Antitrypsin Deficiency Biotechnology Deficiency Hemoglobin Hemoglobinopathies Huntington's Disease Life Sciences Treatment Of Hemophilia Acute Intermittent Porphyria Alnylam Pharmaceuticals Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Autosomal Dominant Polycystic Kidney Disease Beta Thalassemia Biopharmaceutical Biosurgery Products Blastoma
        Hemophilia A

        Haemophilia A (or hemophilia A) is a genetic deficiency in clotting factor VIII, which causes increased bleeding and usually affects males. In the majority of cases it is inherited as an X-linked recessive trait, though there are cases which arise from spontaneous mutations.Factor VIII medication may be used to treat and prevent bleeding in people with haemophilia A.

        More about Hemophilia A
        Browse All Tags